SCHEMBL17796149

SCHEMBL17796149

Nc1cc(Cl)ncc1C(=O)Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 1/20 0.39
SLC9A1 P19634 1/20 0.38
GABRP O00591 2/20 0.36
GABRD O14764 2/20 0.36
GABRA1 P14867 2/20 0.36
GABRB1 P18505 2/20 0.36
GABRG2 P18507 2/20 0.36
GABRB3 P28472 2/20 0.36
GABRA5 P31644 2/20 0.36
GABRA3 P34903 2/20 0.36
GABRA2 P47869 2/20 0.36
GABRB2 P47870 2/20 0.36
GABRA4 P48169 2/20 0.36
GABRE P78334 2/20 0.36
GABRA6 Q16445 2/20 0.36
GABRG1 Q8N1C3 2/20 0.36
GABRG3 Q99928 2/20 0.36
GABRQ Q9UN88 2/20 0.36
NNMT P40261 1/20 0.36
TDP1 Q9NUW8 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7813902 0.86 GABRP (0.47) SIRT6GABRPGABRDGABRA1GABRB1
SCHEMBL17362420 0.86 SIRT6 (0.47) SIRT6SLC9A1GABRPGABRDGABRA1
SCHEMBL26765951 0.84 GABRP (0.38) SIRT6GABRPGABRDGABRA1GABRB1
SCHEMBL29977172 0.80 ABL1 (0.56) ABL1KDM4EALDH1A1LMNAMAPT
SCHEMBL4499056 0.80 ABL1 (0.56) ABL1KDM4EALDH1A1LMNAMAPT
SCHEMBL18929978 0.80 NNMT (0.41) NNMTABL1
SCHEMBL16333365 0.78 NNMT (0.42) SIRT6NNMTNAPRTHAVCR2KDM4E
SCHEMBL29577063 0.78 NNMT (0.42) SIRT6NNMTNAPRTHAVCR2KDM4E
SCHEMBL25426252 0.77 SIRT2 (0.33)
SCHEMBL22117169 0.76 TDP1 (0.33) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206732-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS ARVINAS OPERATIONS, INC. 2025-06-26 US disclosed
WO-2023141570-A9 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS ARVINAS OPERATIONS, INC. (US) 2024-06-27 WO disclosed
US-11548888-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2023-01-10 US disclosed
EP-4087573-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2022-11-16 EP disclosed
EP-3908283-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2021-11-17 EP disclosed
US-20200331911-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2020-10-22 US disclosed
WO-2020146613-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-07-16 WO disclosed
US-9771351-B2 Wnt signaling inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-09-26 US disclosed
US-20160168125-A1 WNT SIGNALING INHIBITOR KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-06-16 US disclosed
EP-3028703-A1 Wnt SIGNALING INHIBITOR Kyowa Hakko Kirin Co., Ltd. (JP) 2016-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548888-B2 KRas G12C inhibitors KRAS, NRAS, HRAS SIRT6 2324/4885SLC9A1 1418/4885GABRP 3033/4885
US-20200331911-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS SIRT6 2324/4885SLC9A1 1418/4885GABRP 3033/4885
US-20250206732-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS KRAS, MDM2, VHL SIRT6 1674/4885SLC9A1 4769/4885GABRP 2754/4885
US-20160168125-A1 WNT SIGNALING INHIBITOR WNT3A, WNT1, WNT3 SIRT6 3863/4885SLC9A1 495/4885GABRP 4673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.